Amubarvimab, previously known as BRII-196 , represents a significant advancement in therapeutic development, particularly concerning its capacity to inhibit the virus . This targeted agent demonstrates https://annieansr873206.blognody.com/50414304/amubarvimab-a-in-depth-analysis-into-brii-196-s-potential